ScreenerHero

SLV Selvita S.A.

GPW · PL · Healthcare · Diagnostics & Research · selvita.com
22.20PLN+1.37%Mkt Cap: 103.18M $P/E: —

Selvita S.A. provides drug discovery, drug development, and contract testing services in Poland. The company offers computer-aided drug design and artificial intelligence solutions, including structure-based drug design,…

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc.
$250.23BUSDP/E 36.4
DHR
Danaher Corporation
$155.51BUSDP/E 39.4
NTRA
Natera, Inc.
$61.35BUSD
LONN
Lonza Group AG
$45.82BUSDP/E 38.1
A
Agilent Technologies, Inc.
$48.29BUSDP/E 33.8
ILMN
Illumina, Inc.
$44.35BUSDP/E 54.8
IQV
IQVIA Holdings Inc.
$43.80BUSDP/E 33.1
WAT
Waters Corporation
$43.21BUSDP/E 111.4
IDXX
IDEXX Laboratories, Inc.
$41.58BUSDP/E 37.0
MTD
Mettler-Toledo International Inc.
$30.89BUSDP/E 34.7
DGX
Quest Diagnostics Incorporated
$25.63BUSDP/E 24.7
GH
Guardant Health, Inc.
$25.12BUSD
LH
Labcorp Holdings Inc.
$25.03BUSDP/E 25.5
RVTY
Revvity, Inc.
$17.56BUSDP/E 75.3
MEDP
Medpace Holdings, Inc.
$17.32BUSDP/E 36.4
CRL
Charles River Laboratories International, Inc.
$14.84BUSD
ERF
Eurofins Scientific SE
$14.05BUSDP/E 26.2
ICLR
ICON Public Limited Company
$12.99BUSDP/E 177.2
BIM
bioMérieux S.A.
$10.02BUSDP/E 20.0
QGEN
Qiagen N.V.
$9.46BUSDP/E 23.2

Key Statistics

Company
Market Cap103.18M USD
Enterprise Value141.07M USD
Revenue (TTM)88.39M USD
Gross Profit74.30M USD
Net Income (TTM)205.90K USD
Revenue/Share19.11 PLN
Last Price22.20 PLN
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees899
CountryPL
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)29.33
PEG—
EV/EBITDA14.55
EV/Revenue1.60
P/S1.15
P/B1.27
EPS (TTM)-0.11
EPS (Forward)—
52W Range
20.207% of range49.40
52W High49.40 PLN
52W Low20.20 PLN
Profitability
Gross Margin80.55%
Oper. Margin-0.80%
EBITDA Margin10.97%
Profit Margin0.22%
ROE0.25%
ROA0.14%
Growth
Revenue Growth-10.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF18.55M USD
CapEx (TTM)1.81M USD
FCF Margin11.24%
FCF Yield9.63%
Net Debt39.26M USD
Net Debt/EBITDA4.05
Balance Sheet
Debt/Equity0.53
Current Ratio0.95
Quick Ratio0.81
Book Value/Sh17.19 PLN
Cash/Share0.90 PLN
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 PLN
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.5 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)35.85 PLN
Upside (mean)+61.5%
Target Range25.00 PLN – 47.10 PLN
25.00+61.5% to mean47.10
# Analysts6
Ownership
Shares Out.18.35M
Float9.75M
Insiders21.18%
Institutions27.30%
Technical
SMA 5026.17 (-15.2%)
SMA 20033.84 (-34.4%)
Beta0.09
S&P 52W Chg14.58%
Avg Vol (30d)28.64K
Avg Vol (10d)35.69K
Technical Indicators
RSI (14)37.5
MACD-1.5063
MACD Signal-1.4436
MACD Hist.-0.0627
BB Upper28.86 PLN
BB Middle23.91 PLN
BB Lower18.96 PLN
BB Width41.44%
ATR (14)1.107 PLN
Vol Ratio (20d)0.92x